LEVOFLOXACIN ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H20FN3O4
Molecular Weight	361.3682
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@]1([H])COc2c3c(cc(c2N4CCN(C)CC4)F)c(=O)c(cn13)C(=O)O

InChI

InChIKey=GSDSWSVVBLHKDQ-JTQLQIEISA-N

InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C18H20FN3O4
Molecular Weight	361.3682
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf

Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV 56 Target ID: CHEMBL2363033 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26525786	Inhibitor 7701	Urinary tract infections Chronic bronchitis Chronic bacterial prostatitis Complicated Skin and Skin Structure Infections Pneumonia Plague
DNA gyrase 25 Target ID: CHEMBL2311225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26459538	Inhibitor 7701	Pneumonia Complicated Skin and Skin Structure Infections Chronic bacterial prostatitis Plague Chronic bronchitis Urinary tract infections

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pneumonia 90 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	DNA gyrase Topoisomerase IV	Approved 7997	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 851040000000
Complicated Skin and Skin Structure Infections 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	DNA gyrase Topoisomerase IV	Approved 7997	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 851040000000
Chronic bacterial prostatitis 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	DNA gyrase Topoisomerase IV	Approved 7997	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 851040000000
Plague 13 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	DNA gyrase Topoisomerase IV	Approved 7997	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 851040000000
Chronic bronchitis 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	DNA gyrase Topoisomerase IV	Approved 7997	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 851040000000
Urinary tract infections 197 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	DNA gyrase Topoisomerase IV	Approved 7997	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 851040000000

C_max

Value	Dose	Analyte	Population
7.9 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.8 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
11.8 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.85 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
2.04 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.3 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
49.6 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
59 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
118 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
111 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
19.88 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
55.3 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
7.6 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.9 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.9 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
5.97 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.6 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	unhealthy, mean 50 years Health Status: unhealthy Age Group: mean 50 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	unhealthy, mean 50 years Health Status: unhealthy Age Group: mean 50 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	unhealthy, mean 50 years Health Status: unhealthy Age Group: mean 50 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.2%) Nausea (0.6%) Vomiting (0.5%) Dizziness (0.3%) Headache (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1172 substrate 1470	inhibitor 1318 substrate 865	inhibitor 1421 substrate 1038	inhibitor 1360

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1268 CYP2B6 679 CYP2C8 761 CYP2C19 1215 OCTN2 66	BCRP 461 CYP1A2 892 CYP2C19 830 UGT1A1 358 UGT1A3 358 UGT1A4 295 UGT1A6 258 UGT1A7 197 UGT1A8 242 UGT1A10 247 OATP1A2 55 OATP2B1 88 OATP1B1 353 OATP1B3 303 P-gp 1223

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP2C9 1362	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	inconclusive	levofloxacin-N-oxide 6
CYP1A2 1406	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: -	no
CYP1A2 1406	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2B6 845	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C8 810	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP3A4 1462	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	weak	levofloxacin-N-oxide 6
CYP2C9 1362	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: -	yes [IC50 210 uM]
OCTN2 71	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/16928358/ Page: -	yes [IC50 6800 uM]
CYP2C19 1277	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	yes	levofloxacin-N-oxide 6
CYP2D6 1455	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	yes	levofloxacin-N-oxide 6

Drug as victim

Target	Modality	Activity	Metabolite
CYP1A2 892	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C19 830	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C9 865	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2D6 1038	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP3A4 1470	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
OATP1B1 353	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
OATP1B3 303	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
OATP2B1 88	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
UGT1A10 247	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A4 295	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A6 258	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A8 242	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
OATP1A2 55	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	yes [Km 136 uM]
BCRP 461	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/17978494/ Page: -	yes
P-gp 1223	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/17978494/ Page: -	yes
UGT1A1 358	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes
UGT1A3 358	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes
UGT1A7 197	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1392	inhibitor 1374 Sources: https://pubmed.ncbi.nlm.nih.gov/16474415/ Page: -

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY34034
1PlusChem LLC	1P0003UE
1PlusChem LLC	1P0018Q1
1PlusChem LLC	1P0025P8
1PlusChem LLC	1P00BISY
1PlusChem LLC	1P00IDPB
A2B Chem	AA04182
A2B Chem	AA57161
A2B Chem	AA99900
A2B Chem	AF36786
A2B Chem	AI56767
A2Z Synthesis	A2Z00017269
AA Blocks	AA0003AY
AA Blocks	AA009WNN
AA Blocks	AA00BI9I
AChemBlock	10413
AK Scientific	A770
AK Scientific	H778
AK Scientific	J10056
AK Scientific	J10174
AK Scientific	J10376
AK Scientific	J11044
AK Scientific	J91234
AK Scientific	S454
AK Scientific	S518
AK Scientific	Z6135
APExBIO	A5511
APExBIO	B1959
AbovChem LLC	HY-B0125
AbovChem LLC	HY-B0330
AbovChem LLC	HY-B0330A
Accela ChemBio Inc	SY010305
Achemo BB	AC-14734
Alfa Chemistry	44170
Alfa Chemistry	ACM118120517
Alinda	IBS-E0013863
Ambeed	A105051
Ambeed	A126121
Ambeed	A264523
Ambeed	A294611
Ambeed	A510593
Ambeed	A718414
Angene	AGN-PC-00EQBI
Angene	AGN-PC-0PMC1X
Angene	AGN-PC-0QZ8V4
Angene	AGN-PC-0R51F4
Apollo Scientific	BIL1009
AstaTech	31131
AstaTech	42399
AstaTech	42421
BLDpharm	BD0022
BLDpharm	BD166967
BLDpharm	BD22744
BLDpharm	BD233964
BLDpharm	BD233965
BLDpharm	BD331969
BLDpharm	BD49090
BOC Sciences	100986-85-4
BOC Sciences	138199-71-0
BOC Sciences	177325-13-2
BOC Sciences	226578-51-4
BOC Sciences	294662-18-3
BOC Sciences	82419-36-1
Bide Pharmatech	BD0022
Bide Pharmatech	BD22744
Bide Pharmatech	BD233964
Bide Pharmatech	BD49090
BioSynth	O-2800
BioSynth	Q-201295
BioSynth	Q-201296
BioSynth	Q-201507
BlocksMatrix Scientific	95318
BlocksMatrix Scientific	95319
Bosche Scientific	L0895
Bosche Scientific	L3394
Bosche Scientific	O2261
Cayman Chemical	20382
Chem Scene	CS-1891
Chem Scene	CS-2218
Chem Scene	CS-4480
Chem-Impex International	15155
ChemDiv	1495-0505
ChemShuttle	138423
ChemShuttle	140533
ChemShuttle	151543
Combi-Blocks	QA-7453
Combi-Blocks	QC-2601
Compound Cloud	149096
Compound Cloud	189546
Compound Cloud	3033924
Compound Cloud	4583
Enamine	EN300-06482
Enamine	Z1766089137
Enamine	Z56761309
Excenen	EX-A1488
Fluorochem	387019
Fluorochem	54449
Hairui	HR104662
Hairui	HR126476
Hairui	HR127302
Hairui	HR141647
Hangzhou APIChem Technology	AC-7593
Hangzhou APIChem Technology	AC-7616
Hangzhou APIChem Technology	AC-7617
Hangzhou Yuhao Chemical Technology	LT1250
Hangzhou Yuhao Chemical Technology	LX3243
HongKong Chemhere	177325-13-2
HongKong Chemhere	294662-18-3
IBScreen	BB_SC-01252
IBScreen	Bio-0713
Innovapharm	BBS-00034040
Innovapharm	BBV-00000206
Innovapharm	STT-00011934
Innovapharm	STT-00466783
KeyOrganics	AS-13719
KeyOrganics	AS-16117
KeyOrganics	AS-20129
KeyOrganics	AS-31796
KeyOrganics	KS-1077
KeyOrganics	KS-5011
Lab Network	LN00193453
Lab Network	LN00235793
Lab Network	LN02063187
Lab Seeker	SC-12664
Lab Seeker	SC-17360
Lab Seeker	SC-19581
Lab Seeker	SC-24784
Lab Seeker	SC-24967
Life Chemicals	F0472-0226
MedChem Express	HY-B0125
MedChem Express	HY-B0330
MedChem Express	HY-B0330A
MolPort	MolPort-000-422-241
MolPort	MolPort-000-758-642
MolPort	MolPort-002-885-835
MolPort	MolPort-005-932-749
MolPort	MolPort-023-219-659
MolPort	MolPort-023-220-556
MolPort	MolPort-023-332-231
MolPort	MolPort-035-813-682
MolPort	MolPort-046-418-558
Molcan	levofloxacin-api
Molcore	MC34034
Molnova	M11584
Molnova	M13377
Molnova	M16061
Molnova	M17748
MuseChem	A000052
MuseChem	A000867
MuseChem	M028107
Oakwood	97613
Otava	111050009
PI Chemicals	PI-12400
PI Chemicals	PI-12401
PI Chemicals	PI-15790
PI Chemicals	PI-21889
Pharmeks	PHAR089137
Pharmeks	PHBB_SC-00825
Princeton BioMolecular Research	OSSL_856852
Princeton BioMolecular Research	OSSL_856862
Ryan Scientific	Glutathione
Selleck Chemicals	S1940
ShangHai Biochempartner	BCP001497
ShangHai Biochempartner	BCP14346
Sigma Aldrich	1362103
Sigma Aldrich	1362103\|USP
Sigma Aldrich	1478108
Sigma Aldrich	1478108\|USP
Sigma Aldrich	28266
Sigma Aldrich	28266\|SIGMA
Sigma Aldrich	33703
Sigma Aldrich	33703\|SIAL
Sigma Aldrich	40922
Sigma Aldrich	40922\|SIAL
Sigma Aldrich	L-038
Sigma Aldrich	L-038\|CERILLIAN
Sigma Aldrich	O0120000
Sigma Aldrich	O0120000\|SIAL
Sigma Aldrich	O8757
Sigma Aldrich	O8757\|SIGMA
Sigma Aldrich	PHR1168
Sigma Aldrich	PHR1168\|SIAL
Sigma Aldrich	PHR1697
Sigma Aldrich	PHR1697\|SIAL
StruChem	SC-12664
StruChem	SC-17360
StruChem	SC-19581
StruChem	SC-24784
StruChem	SC-24967
TargetMol	T0902
TargetMol	T1451
TargetMol	T6567
Tetrahedron	TS16317
Tetrahedron	TS66441
Tetrahedron	TS66442
Tetrahedron	TS69185
Tetrahedron	TS75469
Tetrahedron	TS82522
TimTec	ST073364
Toronto Research Chemicals	L360000
Toronto Research Chemicals	L360253
Toronto Research Chemicals	O245750
Toronto Research Chemicals	O245768
UORSY	PB56838777
Vesino Industrial Co Ltd	VA11432
Vitas-M Laboratory	BBL005605
Vitas-M Laboratory	STK256723
Vitas-M Laboratory	STL047996
W&J PharmaChem	50A129219
W&J PharmaChem	50C104510
Wonderchem	WD055TU
ZINC	ZINC000000538273	http://zinc15.docking.org/substances/ZINC000000538273
eMolecules	108761564
eMolecules	25686002
eMolecules	275134271
eMolecules	295160623
eMolecules	29539002
eMolecules	300016488
eMolecules	300998308
eMolecules	30156173
eMolecules	313085968
eMolecules	44457521
eMolecules	44457522
eMolecules	48660483
eMolecules	494498
eMolecules	498886
eMolecules	50394581
eMolecules	6718901
eMolecules	72973295
eNovation Chemicals	D405132
eNovation Chemicals	D488393
eNovation Chemicals	D759627
mcule	MCULE-1927163841
mcule	MCULE-2011834955
mcule	MCULE-2223333495
mcule	MCULE-3182061888
mcule	MCULE-4652926593
mcule	MCULE-5746531107

PubMed

Title	Date	PubMed
In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.	2001	11447768
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.	2001	11347723
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.	2001	11327197
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.	2001 Apr	11404068
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).	2001 Apr	11404067
Enantioseparation of ofloxacin in urine by capillary electrokinetic chromatography using charged cyclodextrins as chiral selectors and assessment of enantioconversion.	2001 Apr	11379965
In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.	2001 Apr	11322420
[Use of levofloxacine in primary care for outbreaks in COPD].	2001 Apr 15	11334579
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.	2001 Aug 15	11462189
Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration.	2001 Feb	11396281
Quinolones alter defense reactions mediated by macrophages.	2001 Feb	11360919
Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells.	2001 Jan	11349764
[Levofloxacin adverse effects, data from clinical trials and pharmacovigilance].	2001 Jan-Feb	11322015
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.	2001 Jul	11463526
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.	2001 Jul	11463525
New directions in antiinfective therapy for community-acquired pneumonia in the emergency department.	2001 Jul	11446525
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.	2001 Jul	11446524
Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.	2001 Jul	11446523
The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.	2001 Jul	11446520
Levofloxacin and warfarin interaction.	2001 Jul	11444586
The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.	2001 Jul	11418525
Activity of levofloxacin and ciprofloxacin against urinary pathogens.	2001 Jul	11418511
Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?	2001 Jul-Aug	11399859
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.	2001 Jun	11455504
Complicated urinary tract infections in patients with voiding dysfunction.	2001 Jun	11442992
Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy.	2001 Jun	11408986
Levofloxacin failure in a patient with pneumococcal pneumonia.	2001 Jun	11408985
Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece.	2001 Jun	11397616
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.	2001 Jun	11397615
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.	2001 Jun	11389122
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.	2001 Jun	11389113
Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.	2001 Mar	11406752
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.	2001 Mar	11337189
Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice.	2001 Mar	11325396
Treatment of tularemia with levofloxacin.	2001 Mar	11318818
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.	2001 Mar	11318077
A case of renal involvement in persistent immune activation caused by chlamydial salpingitis.	2001 Mar	11315629
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.	2001 May	11388112
Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.	2001 May	11370709
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.	2001 May	11337224
Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery.	2001 May	11328803
Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.	2001 May	11328784
Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.	2001 May	11328779
Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.	2001 May	11328772
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.	2001 May 15	11317266
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.	2001 May-Jun	11448565
Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.	2001 May-Jun	11448564
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.	2001 May-Jun	11448563
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.	2001 May-Jun	11448561
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.	2001 Spring	11310803

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours.

Route of Administration: Other

In Vitro Use Guide

Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:55:15 UTC 2021` Edited by `admin` on `Fri Jun 25 21:55:15 UTC 2021`
Record UNII	RIX4E89Y14
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LEVOFLOXACIN ANHYDROUS

Common Name

English

OFLOXACIN S-(-)-FORM [MI]

Common Name

English

OFLOXACIN S-(-)-FORM

Common Name

English

LEVOFLOXACIN [WHO-DD]

Common Name

English

NSC-758709

Code

English

LEVOFLOXACIN [INN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

J01MA12